Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BARD C R INC /NJ/BCR · Entity 170698 | Director | December 29, 2017 | January 03, 2018 |
| Carlyle Group Inc.CG · Entity 3316 | Director | May 01, 2026 | May 01, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | August 26, 2026 | August 27, 2026 |
| LOEWS CORPL · Entity 3231 | Director | March 03, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 1
1 source rowRow 1 · 2017-12-29 · Disposition to issuer · Disposed 4,520 · Balance 0 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,596.9 |
Reported balance
After 2017-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-29 · Grant · Acquired 83.42 · Balance 20,596.9 F2: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F3: Conversion is 1 for 1. F4: Phantom stock units are settled in cash upon termination of service as director. F5: Includes 32.86 units for dividend credits. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-12-29 · Disposition to issuer · Disposed 20,596.9 · Balance 0 F2: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F3: Conversion is 1 for 1. F6: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement. |
| Share Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-29 · Disposition to issuer · Disposed 17,808 · Balance 0 F7: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3: Conversion is 1 for 1. F8: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").
F2: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.
F3: Conversion is 1 for 1.
F4: Phantom stock units are settled in cash upon termination of service as director.
F5: Includes 32.86 units for dividend credits.
F6: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.
F7: Units granted under the Company's Stock Equivalent Plan for Outside Directors.
F8: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.
Carlyle Group Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,849 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 4,450 · Balance 47,849 F1: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Issuer's Board of Directors on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Issuer's Board of Directors on such vesting date.
GILEAD SCIENCES, INC.
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,894 |
Ending reported balance
After 2026-08-26 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-26 · Exercise / conversion · Acquired 7,718 · Balance 20,612 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Row 2 · 2026-08-26 · Sale · Disposed 3,118 · Balance 17,494 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2: Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 3 · 2026-08-26 · Sale · Disposed 4,600 · Balance 12,894 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F3: Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 4 · 2026-08-26 · Exercise / conversion · Acquired 10,282 · Balance 23,176 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Row 5 · 2026-08-26 · Sale · Disposed 3,402 · Balance 19,774 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F4: Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 6 · 2026-08-26 · Sale · Disposed 6,880 · Balance 12,894 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F5: Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.67 · Expires 2030-10-22 | Direct | 0 |
Reported balance
After 2026-08-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-26 · Exercise / conversion · Disposed 7,718 · Balance 0 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F6: 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.35 · Expires 2032-05-05 | Direct | 5,569 |
Reported balance
After 2026-08-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-26 · Exercise / conversion · Disposed 10,282 · Balance 5,569 F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F7: 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.
F2: Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4: Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5: Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F6: 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020.
F7: 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021.
LOEWS CORP
Report date March 03, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,845 |
Ending reported balance
After 2025-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-03 · Exercise / conversion · Acquired 2,250 · Balance 12,095 F1: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. Row 2 · 2025-03-03 · Disposition to issuer · Disposed 1,053 · Balance 11,042 F1: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. Row 3 · 2025-03-03 · Sale · Disposed 1,197 · Balance 9,845 F1: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 · Expires 2025-03-31 | Direct | 0 |
Reported balance
After 2025-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-03 · Exercise / conversion · Disposed 2,250 · Balance 0 F1: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. F2: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024.
F2: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
UNITEDHEALTH GROUP INC
Report date June 05, 2012 · Filed June 07, 2012
Section 16 reporting ended · disclosed 2012-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,908.836 |
Reported balance
After 2012-06-05 transaction · row 1
1 source rowRow 1 · 2012-06-05 · Tax withholding · Disposed 7,211 · Balance 119,908.836 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,282 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · derivative · entry 8 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,569 Underlying: Common Stock · 10,282 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $60.67 | $0.00 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · derivative · entry 7 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,718 shares Expires 2030-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F6 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,880 | $148.82 | $1,023,900.18 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 6 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,894 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F5 · price: Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,402 | $148.24 | $504,296.49 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 5 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,774 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F4 · price: Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,282 | $61.35 | $630,800.70 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,600 | $148.82 | $684,590.40 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,894 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F3 · price: Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,118 | $148.31 | $462,432.45 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 · price: Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,718 | $60.67 | $468,251.06 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:27 UTC | Carlyle Group Inc. CG · Entity 3316 | GrantCommon Stock | 4,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029467 · wk-form4_1777674454.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,849 F1 · kind: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Issuer's Board of Directors on such vesting date. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,884 | $0.00 Strike: $130.84 | $0.00 |
DisclosureSEC source: 0001213307-26-000003 · wk-form4_1777926175.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884 Underlying: Common Stock · 4,884 shares Expires 2036-04-30 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001213307-26-000003 · wk-form4_1777926175.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,894 F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 22:02 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001213307-25-000005 · wk-form4_1764108170.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,399 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 22:02 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 11,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001213307-25-000005 · wk-form4_1764108170.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,599 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| May 07, 2025 Filed May 8, 2025 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,809 | $0.00 Strike: $98.90 | $0.00 |
DisclosureSEC source: 0001127602-25-013752 · form4.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 Underlying: Common Stock · 6,809 shares Expires 2035-05-07 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025. Read SEC document |
| May 07, 2025 Filed May 8, 2025 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013752 · form4.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,748 F1 · security: Represents 1,516 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 7, 2025. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:24 UTC | Carlyle Group Inc. CG · Entity 3316 | GrantCommon Stock | 5,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001527166-25-000058 · wk-form4_1746217485.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,305 F1 · kind: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2026, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:17 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0000060086-25-000068 · wk-form4_1741123039.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:17 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,197 | $86.87 | $103,983.39 |
DisclosureSEC source: 0000060086-25-000068 · wk-form4_1741123039.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,845 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:17 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,053 | $86.89 | $91,495.17 |
DisclosureSEC source: 0000060086-25-000068 · wk-form4_1741123039.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,042 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:17 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $40.61 | $91,372.50 |
DisclosureSEC source: 0000060086-25-000068 · wk-form4_1741123039.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:16 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $42.52 | $0.00 |
DisclosureSEC source: 0000060086-24-000210 · wk-form4_1733260608.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:16 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,146 | $86.81 | $99,484.26 |
DisclosureSEC source: 0000060086-24-000210 · wk-form4_1733260608.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,845 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:16 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,104 | $86.80 | $95,827.20 |
DisclosureSEC source: 0000060086-24-000210 · wk-form4_1733260608.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,991 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:16 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $42.52 | $95,670.00 |
DisclosureSEC source: 0000060086-24-000210 · wk-form4_1733260608.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 21:58 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 13,280 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-131912 · ownership.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,070 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $41.98 | $0.00 |
DisclosureSEC source: 0000060086-24-000169 · wk-form4_1725480910.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,088 | $81.41 | $88,574.08 |
DisclosureSEC source: 0000060086-24-000169 · wk-form4_1725480910.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,845 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,162 | $81.42 | $94,610.04 |
DisclosureSEC source: 0000060086-24-000169 · wk-form4_1725480910.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,933 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $41.98 | $94,455.00 |
DisclosureSEC source: 0000060086-24-000169 · wk-form4_1725480910.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:17 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.83 | $0.00 |
DisclosureSEC source: 0000060086-24-000135 · wk-form4_1717532228.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:17 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 963 | $75.80 | $72,995.40 |
DisclosureSEC source: 0000060086-24-000135 · wk-form4_1717532228.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,845 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $75.60 and $76.59. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:17 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,287 | $76.59 | $98,571.33 |
DisclosureSEC source: 0000060086-24-000135 · wk-form4_1717532228.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,808 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:17 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.83 | $98,617.50 |
DisclosureSEC source: 0000060086-24-000135 · wk-form4_1717532228.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| May 14, 2024 Filed May 14, 2024 20:35 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000122 · wk-form4_1715718894.xml · derivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,288 Underlying: Common Stock · 1,288 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (each, an "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: These RSUs vest on May 14, 2025. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F2 · derivative.expiration_date: These RSUs vest on May 14, 2025. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| May 09, 2024 Filed May 9, 2024 12:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000097 · wk-form4_1715258415.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 9, 2023, the Reporting Person was granted 1,706 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F3 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 9, 2023, the Reporting Person was granted 1,706 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 09, 2024 Filed May 9, 2024 12:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000097 · wk-form4_1715258415.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,648 | $0.00 Strike: $64.92 | $0.00 |
DisclosureSEC source: 0001127602-24-014814 · form4.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014814 · form4.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,232 F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 01, 2024 Filed May 3, 2024 21:28 UTC | Carlyle Group Inc. CG · Entity 3316 | GrantCommon Stock | 5,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053079 · ownership.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,350 F1 · shares: These securities are restricted stock unit awards granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2025, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:04 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0000060086-24-000070 · wk-form4_1709597082.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:04 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 951 | $75.01 | $71,334.51 |
DisclosureSEC source: 0000060086-24-000070 · wk-form4_1709597082.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,139 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $75.00 and $75.07. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:04 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,299 | $75.07 | $97,515.93 |
DisclosureSEC source: 0000060086-24-000070 · wk-form4_1709597082.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,090 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:04 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.37 | $97,582.50 |
DisclosureSEC source: 0000060086-24-000070 · wk-form4_1709597082.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:23 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $47.84 | $0.00 |
DisclosureSEC source: 0000060086-23-000204 · wk-form4_1701724996.xml · derivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:23 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 715 | $70.16 | $50,164.40 |
DisclosureSEC source: 0000060086-23-000204 · wk-form4_1701724996.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,139 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $69.93 and $70.52. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:23 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,535 | $70.08 | $107,572.80 |
DisclosureSEC source: 0000060086-23-000204 · wk-form4_1701724996.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,854 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:23 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $47.84 | $107,640.00 |
DisclosureSEC source: 0000060086-23-000204 · wk-form4_1701724996.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:54 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000113 · wf-form4_168374844558358.xml · derivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:54 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000113 · wf-form4_168374844558358.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 09, 2023 Filed May 10, 2023 19:54 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000113 · wf-form4_168374844558358.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706 Underlying: Common Stock · 1,706 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F3 · derivative.expiration_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.